| Literature DB >> 32410070 |
Laxmaiah Manchikanti1,2,3, Vanila Singh4, Alan D Kaye5,6,7, Joshua A Hirsch8,9.
Abstract
The treatment of noncancer pain in the United States and globally is met with significant challenges, resulting in profound physical, emotional, and societal costs. Based on this need, numerous modalities have been proposed to manage chronic pain, including opioid and nonopioid interventions as well as surgical approaches. Thus, the future of pain management continues to be mired in evolving concepts and constant debates. Consequently, it is crucial to understand the past as we move towards the future. The evolution of lessons for better pain management at present and for the future starting from the 1990s to the present date are reviewed and emphasized with a focus on learning from the past for the future. This review summarizes the evolution of multiple modalities of treatments, including multidisciplinary programs, multimodal therapy, interventional techniques, opioid therapy, other conservative modalities, and surgical interventions. This review emphasizes the individual, patient-centered development of an effective pain treatment plan after proper evaluation to establish a diagnosis. It includes measurable outcomes that focus on improvements in the quality of life and activities of daily living, as well as improvement in pain and function and, most importantly, return to productive citizenship. It is crucial that the knowledge of best practices be advanced, along with emphasis on lessons learned in the past to provide best practices for better pain management.Entities:
Keywords: Best practices; Better pain management; Evidence-based medicine; Interventional techniques; Opioid epidemic
Year: 2020 PMID: 32410070 PMCID: PMC7648810 DOI: 10.1007/s40122-020-00170-8
Source DB: PubMed Journal: Pain Ther
Fig. 1National drug overdose deaths (number among all ages, 1999–2017). Reproduced from NIDA. (2020, March 10). Overdose Death Rates. Retrieved from https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates on 2020, April 20
Fig. 2Quantification of opioid deaths. Reproduced from NIDA. (2020, March 10). Overdose Death Rates. Retrieved from https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates on 2020, April 20
Fig. 3Comparative analysis of epidural and adhesiolysis procedures, facet joint interventions, and sacroiliac joint blocks, disc procedures, and other types of nerve blocks, all of which are interventional techniques.
Reproduced from Manchikanti Let al. [56]
Ten-step process for opioid prescribing for chronic cancer pain based on ASIPP guidelines of chronic opioid therapy for chronic non-cancer pain
| 1. Initial steps of opioid therapy |
| Comprehensive assessment |
| Risk stratification |
| 2. Establish diagnosis |
| X-rays, MRI, CT, neurophysiologic studies |
| Psychological evaluation (basic) |
| Precision diagnostic interventions (optional) |
| Consultation(s) as needed |
| 3. Establishing medical necessity |
| Physical diagnosis |
| Non-opioid therapy |
| Physical modalities |
| Behavioral interventions (optional) |
| Interventional pain management (optional) |
| Other alternatives |
| Consultation(s) as needed |
| 4. Establishing treatment goals |
| Decrease pain by 30% and/or increase function by 30% |
| Minimal adverse effects |
| 5. Assessment of effectiveness of opioid therapy |
| 6. Informed decision-making |
| Controlled substance agreement |
| Random evaluations including pill counts and urine drug testing |
| 7. Initial treatment (8–12 weeks) |
| Stratification of risk |
| Understanding opioids |
| Initiation with low-dose short-acting opioid therapy |
| Titrate |
| 8. Adherence monitoring |
| Prescription drug monitoring programs |
| Urine drug testing (follow urine drug testing algorithm) |
| Pill counts |
| Behavioral assessment during each visit |
| 9. Monitoring and managing side effects |
| Driving |
| Sedation |
| Constipation |
| Breathing |
| 10. The final phase |
| Chronic opioid therapy may be continued, with continuous adherence monitoring |
| Methadone and buprenorphine are recommended for use in late stages after failure of other opioid therapy and only by clinicians with specific training in the risks and uses |
| A trial of opioid rotation may be considered for patients requiring escalating doses |
| Chronic opioid therapy should be monitored for adverse effects and to manage them appropriately |
Fig. 4A comprehensive algorithm for the evaluation and management of chronic spinal pain.
Reproduced from Manchikanti et al. [5]
CDC recommendations for opioid therapy for chronic noncancer pain
| 1. Opioids are not a first-line therapy |
| 2. Establish goals for pain and function |
| 3. Discuss risks and benefits |
| 4. Opioid selection, dosage, duration, follow-up, and discontinuation |
| 4.1 Use immediate-release opioids when starting |
| 4.2 Use the lowest effective dose |
| 4.3 Prescribe short durations for acute pain |
| 4.4 Evaluate benefits and harms frequently |
| 5. Assessing risk and addressing harms |
| 5.1 Use strategies to mitigate risk |
| 5.2 Review PDMP data |
| 6. Use urine drug testing |
| 7. Avoid concurrent opioid and benzodiazepine prescribing |
| 8. Offer treatment for opioid use disorder |
Five-point strategy to combat the opioid crisis.
Reproduced from U.S. Department of Health and Human Services. Available from https://www.hhs.gov/opioids/about-the-epidemic/hhs-response/index.html
| 1. Access: better prevention, treatment, and recovery services |
| HHS issued over $800 million in grants in 2017 to support treatment, prevention, and recovery, while making it easier for states to receive waivers to cover treatment through their Medicaid programs. (Issued five such SUD waivers since PHE declaration.) |
| 2. Data: better data on the epidemic |
| HHS is improving our understanding of the crisis by supporting more timely, specific public health data and reporting, including through accelerating CDC’s reporting of drug overdose data |
| 3. Pain: better pain management |
| HHS wants to ensure everything we do—payments, prescribing guidelines, and more—promotes healthy, evidence-based methods of pain management |
| 4. Overdoses: better targeting of overdose-reversing drugs |
| HHS works to better target the availability of lifesaving overdose-reversing drugs. The president’s 2019 budget includes $74 million in new investments to support this goal |
| 5. Research: better research on pain and addiction |
| HHS supports cutting edge research on pain and addiction, including through a new NIH public–private partnership |
Fig. 5Chronic pain management consists of five treatment approaches informed by four critical topics.
Reproduced from U.S. Department of Health and Human Services. Pain Management Best Practices Inter-Agency Task Force. Final Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations. May 9, 2019. Available from: https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html
| Treatment of non-cancer pain in the United States and globally continues to face significant challenges, resulting in emotional and societal costs. |
| The future of pain management continues to be debated on a daily basis. Those involved in pain management, including patients, officials, and physicians, are focusing on advances. However, these advances, and the future evolution of interventional pain management, may be based on lessons learned in the past and present. |
| This review illustrates substantial variations in the management of chronic non-cancer pain. |
| The review also illustrates the evolution and numerous issues related to the opioid epidemic, and growing utilization and costs of numerous available modalities, and the demise of multidisciplinary clinics in conjunction with increasing disability. |
| Future research and advocacy efforts will be necessary to demonstrate the benefit of multidisciplinary clinics and multimodal approaches to the management of chronic pain in order to improve the quality of life and provide appropriate access to effective modalities of treatments focusing on non-opioid therapy. |